Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Trial Profile

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Pramlintide (Primary)
  • Indications Hypoglycaemia
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2017 Planned End Date changed from 1 May 2015 to 1 Oct 2018.
    • 25 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top